Carrasco-Garrido, PilarFernández-de-Las-Peñas, CésarHernández-Barrera, ValentínPalacios-Ceña, DomingoJiménez-Trujillo, IsabelGallardo-Pino, Carmen2024-01-082024-01-082022-09-08Carrasco-Garrido P, Fernández-de-Las-Peñas C, Hernández-Barrera V, Palacios-Ceña D, Jiménez-Trujillo I, Gallardo-Pino C. Benzodiazepines and Z-hypnotics consumption in long-COVID-19 patients: Gender differences and associated factors. Front Med (Lausanne). 2022; 9:975930. doi: 10.3389/fmed.2022.9759302296858Xhttps://hdl.handle.net/10115/28241Publicación científica en revista indexada con índice de calidad relativo, incluida en los catálogos del Journal Citation Reports (JCR). La revista científica Frontiers in Medicine pertenece y al segundo cuartil (Q2) de su categoría Medicine, General & Internal (SCIE): 58/177. Factor de Impacto en el año 2022: 3.9 https://pubmed.ncbi.nlm.nih.gov/36160133/#full-view-affiliation-2 Este artículo deriva de un Proyecto de Investigación The Long Covid Experience Study. Evolución, Caracterización Clínica, Molecular y Genética y Tratamiento de los Síntomas post-COVID (COVID Persistente) financiado por la Comunidad de Madrid y la Unión Europea, a través del Fondo Europeo de Desarrollo Regional (FEDER), Recursos REACT-UE del Programa Operativo de Madrid 2014-2020, financiado como parte de la respuesta de la Unión Europea a la pandemia de COVID-19 (LONG-COVID-EXP-CM). Investigadora Principal del Subproyecto 6 “Perfil fármaco-epidemiológico del paciente con COVID persistente” : Pilar Carrasco Garrido. https://www.longcovid.eu/subproyecto-6-perfil-farmaco-epidemiologico/Background: Psychotropic drug consumption has increased during the COVID-19 pandemic. We describe here the prevalence and identifying factors associated with Benzodiazepine (BZD) and Z-hypnotics use among a sample of Spanish adults suffering from long-COVID-19 syndrome, from a gender perspective. Materials and methods: Data were anonymously collected between 15th December 2021 and 15th March 2022. The collection form consisted of several questions gathering sociodemographic information, post-COVID symptom, health profile, and pharmacological drug intake. Using logistic multivariate regression models, we estimated the independent effect of each of these variables on self-medicated consumption. Three models were generated (female, male, and both gender). Results: Prevalence of BZD and Z-hypnotics use was 44.9% (46.5% for women; 37.8% for men). Zolpidem was the most consumed drug among male (20.7%), and lorazepam in female (31.1%). Patterns of drug consumption among female were related with number of post-COVID symptoms and smoking habit (AOR 2.76, 95%CI 1.16-6.52). Males under 40 years of age are more likely to consume BZD and Z-hypnotics (AOR 5.52, 95%CI 1.08-28.27). Conclusion: The prevalence of consumption of BZD and Z-hypnotics in those subjects with long-COVID-19 in our study reaches values of 44.9%. Women with long-COVID-19 declare a higher prevalence of consumption than men. Predictors of BZD and Z-hypnotic in men were, age and number of medication use. Smoking habit and the number of post-COVID symptoms were predictive variables in women.engAttribution 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/long-COVID-19benzodiazepineZ-hypnoticsgenderpredictorsinfo:eu-repo/semantics/article10.3389/fmed.2022.975930info:eu-repo/semantics/embargoedAccess